Amneal Pharmaceuticals (AMRX) said Thursday that the US Food and Drug Administration has approved Brekiya injection to treat migraines with or without aura and the acute treatment of cluster headaches in adults.
Brekiya is the company's brand name for dihydroergotamine.
Shares of Amneal Pharmaceuticals were up more than 6% in recent premarket acitivty.
Price: 7.80, Change: +0.45, Percent Change: +6.12
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.